About Taysha Gene Therapies, Inc. - Common Stock (TSHA)
Taysha Gene Therapies Inc is a biotechnology company focused on developing and delivering innovative gene therapies for the treatment of various neurological diseases, particularly genetic disorders that impact the central nervous system. By leveraging advanced technologies, Taysha aims to create transformative therapies that address the underlying causes of these diseases, providing hope for patients with limited treatment options. The company's research and development efforts emphasize collaboration with leading academic institutions and experts to advance its pipeline of gene therapy products toward clinical application. Read More
Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.
Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
